ClinicalTrials.gg
Sign In

Drug

Tagitanlimab clinical trials

studies test it
10
open now
6
in phase 3
1
first study started
2018

Keep track of what changes. Save the tagitanlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

KL-A167
6
Tagitanlimab
4

Combined with it in one product

Sacituzumab Tirumotecan + Tagitanlimab
1
Sacituzumab Tirumotecan plus Tagitanlimab
1

Studies by the year they started

10 studies that test it; most in 2025 (3)

Studies that test tagitanlimab, by start year
YearStudies
20181
20191
20222
20253
20263

By phase

A phase 1/2 study counts in both.

Phase 2
9
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Nasopharyngeal Carcinoma
2
Triple Negative Breast Neoplasms
2
Esophageal Squamous Cell Carcinoma
1
Prostatic Neoplasms
1

Who runs them

Industry 4 · Other 6

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (4) · West China Hospital (2) · Peking Union Medical College Hospital (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Tianjin Medical University Second Hospital (1)

Often tested with

Tested in the same studies.

Sacituzumab tirumotecan (5) · Sacituzumab govitecan (1)

Studies

Open first, then newest update. How each study uses tagitanlimab is read from its arms, and is right about nine times in ten.

Testing it · 10

Given in every arm · 2 — tagitanlimab is usual care beside what is tested

Codes

What other systems call tagitanlimab · ClinicalTrials.gg INT016709

  • UNII (FDA) GUY458P83PTAGITANLIMABOne source FDA
  • NCI Thesaurus C163992TagitanlimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.